Storylines

The big science stories, followed.

Some discoveries are not one day's news but a story that unfolds over months. Each storyline is one ongoing science arc, kept as a dated, sourced timeline the morning letter extends. Every promise made along the way is tracked until it is kept or broken.

Storylines: 8
Dated beats: 24
Promises tracked: 2
Still open: 2

Life Sciences & Medicine Active GLP-1 drugs, beyond weight loss The GLP-1 drugs are turning out to change mood, behavior and the brain's relationship with food, not just body weight, as coverage expands to older adults. Latest · Jul 7, 2026 Cleveland Clinic researchers analyzed records from 2,133 people with type 2 diabetes and peripheral artery disease and found those prescribed GLP-1 receptor agonists like semaglutide had a 48 percent lower risk of major amputation, a 37 percent lower risk of minor amputation, and a 36 percent lower risk of circulation-restoring procedures over five years, compared to a matched metformin group. They were also 26 percent less likely to die from any cause. Whether the benefit comes from weight loss, blood sugar control, or a direct effect on blood vessel walls remains unclear. 4 beats The story so far Life Sciences & Medicine Active The many-fronted fight against Alzheimer's Researchers are attacking Alzheimer's from several directions at once: the biology of how it spreads, drugs that reprogram the brain's immune cells, and blood tests that could catch it years early. Latest · Jul 7, 2026 Mass General Brigham researchers confirmed for the first time in humans that the BCG tuberculosis vaccine can cross the blood-brain barrier into cerebrospinal fluid. In healthy older adults without existing Alzheimer's pathology, BCG shifted amyloid-beta levels downward in cerebrospinal fluid while raising them in the bloodstream, suggesting the vaccine helped push the protein out of the central nervous system. The protective shift was absent in participants who already had established Alzheimer's biomarkers, indicating timing is critical. 5 beats 1 promise, 1 open The story so far Technology & Innovation Active The clean-energy tipping point Solar power and storage are crossing milestones that reorder the grid, even against policy headwinds. Latest · Jul 6, 2026 Solar panels built over California irrigation canals were shown to generate power while also cutting water loss to evaporation. 3 beats The story so far Natural Sciences Active Building a living cell from parts Scientists are assembling the minimum machinery of life from scratch, testing whether the core functions of a living cell need anything mysterious at all. Latest · Jul 2, 2026 A synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, with about 30 percent still carrying DNA after five generations. 2 beats The story so far Psychology & Behavioral Science Active Psilocybin's move into the clinic Once taboo, psilocybin is being tested as a fast-acting treatment for depression and suicidal thoughts, with early and surprising signals in advanced dementia. Latest · Jun 27, 2026 A report described psilocybin temporarily restoring speech and mobility in a case of advanced Alzheimer's. 3 beats The story so far Life Sciences & Medicine Active Switching mammal regeneration back on Mammals scar instead of regrow, but researchers are finding the regenerative machinery is silenced rather than lost, and can sometimes be switched back on. Latest · Jun 27, 2026 Epigenetic editing that switches genes on and off without changing the DNA sequence entered human trials for muscular dystrophy. 2 beats The story so far Technology & Innovation Active Brain implants leave the lab Brain-computer interfaces are moving from lab demos that needed a technician to devices people use unaided at home, restoring speech and movement to people with paralysis. Latest · Jun 19, 2026 Harrell's system let him read aloud to his daughter, and an AI voice reconstruction made his speech about 20 percent more intelligible in noise. 3 beats 1 promise, 1 open The story so far Natural Sciences Active Our ancient relatives, still in our genes Ancient human relatives like the Denisovans are turning out to still shape modern immune systems, and the gaps in our genetic databases matter for health. Latest · Jun 19, 2026 Researchers catalogued more than 3,000 Denisovan genetic variants active in modern immune cells, with some Papua New Guinean populations carrying up to about 5 percent Denisovan DNA. 2 beats The story so far

Every beat was reported in our daily letter on its date and links onward to the primary study. Every promise is tracked until it is kept or broken, never quietly dropped.

The storylines move every morning.